Results 11 to 20 of about 5,796 (217)

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in-depth review of mechanisms of action, failure factors, and future perspectives. [PDF]

Pediatr Allergy Immunol
Evolution of RSV immunoprophylaxis: from the palivizumab era to next‐generation monoclonal antibodies and future perspectives. Created in BioRender. Abstract The burden of respiratory syncytial virus (RSV) remains a major global health concern in early childhood, responsible for substantial morbidity, hospitalizations, and deaths, particularly in ...
Bizot E, Portet Sulla V, Vauloup-Fellous C, Rameix-Welti MA, Gajdos V, Seddiki N.   +5 more
europepmc   +2 more sources

Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection

BMC Pediatrics, 2021
Background The prophylactic use of anti-respiratory syncytial virus (RSV) antibody (palivizumab) for severe RSV infection is not approved in Japan in specified groups of infants with neuromuscular diseases or other rare diseases associated with reduced ...
Masaaki Mori, Shinichi Watabe, Tomoaki Taguchi, Hisaya Hasegawa, Mika Ishige, Naoyuki Tanuma, Akihiro Hirakawa, Ryuji Koike, Satoshi Kusuda   +8 more
doaj   +1 more source

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. [PDF]

PLoS ONE, 2015
To evaluate the safety and tolerability of palivizumab for RSV prophylaxis in high-risk children in everyday practice.High-risk children prophylaxed against RSV infection were recruited into a prospective, observational, Canadian RSV Evaluation Study of ...
Jinghan Jenny Chen, Parco Chan, Bosco Paes, Ian Mitchell, Abby Li, Krista L Lanctôt, CARESS investigators   +6 more
doaj   +1 more source

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children

Human Vaccines & Immunotherapeutics, 2021
To date, there is no consensus regarding palivizumab prophylaxis for respiratory syncytial virus infection. The purpose of this study is to assess the effectiveness of palivizumab prophylaxis to prevent respiratory syncytial virus-related infection ...
Natividad Viguria, Ana Navascués, Regina Juanbeltz, Alberto Echeverría, Carmen Ezpeleta, Jesús Castilla   +5 more
doaj   +1 more source

Quantitative Analysis of Antibody Survival across the Infant Digestive Tract Using Mass Spectrometry with Parallel Reaction Monitoring

Foods, 2020
Orally delivered antibodies may be useful for the prevention of enteric pathogen infection, but to be effective they need to survive intact across digestion through the gastrointestinal tract.
Bum Jin Kim, Jiraporn Lueangsakulthai, Baidya Nath P. Sah, Brian Scottoline, David C. Dallas   +4 more
doaj   +1 more source

Development and Validation of a New Set of Primers for Identification of Circulating Lineages and Palivizumab/Nirsevimab Resistance in HRSV Isolates from Cabo Verde. [PDF]

Trop Med Infect Dis
Reyes-Zuluaga MP, Pérez-Pérez JA, Correia W, de Pina Araújo IIM, Carmelo E.   +4 more
europepmc   +3 more sources

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review

BMJ Paediatrics Open, 2021
In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks.
Marina Davoli, Federico Marchetti, Antonio Addis, Valeria Belleudi, Marco Finocchietti   +4 more
doaj   +1 more source

Palivizumab

Reactions Weekly, 2018
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
  +5 more sources

Does Prophylaxis Against Respiratory Syncytial Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?

Journal of Behçet Uz Children's Hospital, 2021
Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun, İbrahim İlker Çetin, Hazım Alper Gürsu   +2 more
doaj   +1 more source

Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals. [PDF]

MedComm (2020)
Respiratory syncytial virus (RSV) causes substantial global morbidity, particularly in infants and elderly populations. This review summarizes key viral pathogenesis mechanisms and highlights recent advances in both prophylactic (vaccines, antibodies) and therapeutic (antiviral agents) strategies against RSV.
Liang X, Yin Y, Lin Y, Chen S, Qian Q, Yuan J, Yang L, Yang Y.   +7 more
europepmc   +2 more sources